203 related articles for article (PubMed ID: 26883150)
1. Isatin derivatives with activity against apoptosis-resistant cancer cells.
Evdokimov NM; Magedov IV; McBrayer D; Kornienko A
Bioorg Med Chem Lett; 2016 Mar; 26(6):1558-1560. PubMed ID: 26883150
[TBL] [Abstract][Full Text] [Related]
2. The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds.
Guo H; Diao QP
Curr Top Med Chem; 2020; 20(16):1499-1503. PubMed ID: 32156238
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of isatin/triazole conjugates that induce apoptosis and inhibit migration of MGC-803 cells.
Yu B; Wang SQ; Qi PP; Yang DX; Tang K; Liu HM
Eur J Med Chem; 2016 Nov; 124():350-360. PubMed ID: 27597411
[TBL] [Abstract][Full Text] [Related]
4. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel isatin-based derivatives targeting cell cycle checkpoint pathways as potential anticancer agents.
Yousef MA; Ali AM; El-Sayed WM; Qayed WS; Farag HHA; Aboul-Fadl T
Bioorg Chem; 2020 Dec; 105():104366. PubMed ID: 33212312
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.
Ke S; Shi L; Yang Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4628-31. PubMed ID: 26320625
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and in silico studies of potential activators of apoptosis and carbonic anhydrase inhibitors on isatin-5-sulfonamide scaffold.
Krymov SK; Scherbakov AM; Salnikova DI; Sorokin DV; Dezhenkova LG; Ivanov IV; Vullo D; De Luca V; Capasso C; Supuran CT; Shchekotikhin AE
Eur J Med Chem; 2022 Jan; 228():113997. PubMed ID: 34902732
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives.
Teng YO; Zhao HY; Wang J; Liu H; Gao ML; Zhou Y; Han KL; Fan ZC; Zhang YM; Sun H; Yu P
Eur J Med Chem; 2016 Apr; 112():145-156. PubMed ID: 26890120
[TBL] [Abstract][Full Text] [Related]
10. Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents.
Ibrahim HS; Abou-Seri SM; Ismail NSM; Elaasser MM; Aly MH; Abdel-Aziz HA
Eur J Med Chem; 2016 Jan; 108():415-422. PubMed ID: 26706352
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties.
Zebbiche Z; Tekin S; Küçükbay H; Yüksel F; Boumoud B
Arch Pharm (Weinheim); 2021 May; 354(5):e2000377. PubMed ID: 33368627
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in isatin hybrids as potential anticancer agents.
Ding Z; Zhou M; Zeng C
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and apoptosis inducing studies of triazole linked 3-benzylidene isatin derivatives.
Nagarsenkar A; Guntuku L; Guggilapu SD; K DB; Gannoju S; Naidu VGM; Bathini NB
Eur J Med Chem; 2016 Nov; 124():782-793. PubMed ID: 27639369
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents.
Ramshid PK; Jagadeeshan S; Krishnan A; Mathew M; Nair SA; Pillai MR
Med Chem; 2010 Sep; 6(5):306-12. PubMed ID: 21073435
[TBL] [Abstract][Full Text] [Related]
16. Isatin-azole hybrids and their anticancer activities.
Hou Y; Shang C; Wang H; Yun J
Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
[TBL] [Abstract][Full Text] [Related]
17. Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.
Rana S; Blowers EC; Tebbe C; Contreras JI; Radhakrishnan P; Kizhake S; Zhou T; Rajule RN; Arnst JL; Munkarah AR; Rattan R; Natarajan A
J Med Chem; 2016 May; 59(10):5121-7. PubMed ID: 27077228
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel 1H-1,2,3-triazole tethered C-5 substituted uracil-isatin conjugates and their cytotoxic evaluation.
Kumar K; Sagar S; Esau L; Kaur M; Kumar V
Eur J Med Chem; 2012 Dec; 58():153-9. PubMed ID: 23124212
[TBL] [Abstract][Full Text] [Related]
19. Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.
Abdalla AN; Di Stefano M; Poli G; Tuccinardi T; Bader A; Vassallo A; Abdallah ME; El-Readi MZ; Refaat B; Algarni AS; Ahmad R; Alkahtani HM; Abdel-Aziz AA; El-Azab AS; Alqathama A
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011321
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity.
Havrylyuk D; Zimenkovsky B; Vasylenko O; Gzella A; Lesyk R
J Med Chem; 2012 Oct; 55(20):8630-41. PubMed ID: 22992049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
